Neither rifaximin nor norfloxacin, both poorly absorbable antibiotics, significantly reduces hepatic venous pressure gradient in patients with portal hypertension and cirrhosis, a recent study has found.
Epeleuton, a second‐generation synthetic n‐3 fatty acid derivative of eicosapentaenoic acid, falls short of improving alanine aminotransferase or liver stiffness in patients with nonalcoholic fatty liver disease (NAFLD), according to a study. However, it has potential for cardiovascular risk reduction by simultaneously targeting hypertriglyceridemia, hyperglycaemia, and systemic inflammation.
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.